Travers Smith LLP has advised longstanding client Kester Capital and other selling shareholders on the sale of the Frontier Medical Group to Agilitas Private Equity.
The Frontier Medical Group is a leading medical device manufacturer that focuses on skin and wound care. Founded in 1997 through collaboration with NHS clinicians from the University Hospital of Wales in Cardiff, the group has over 25 years’ experience designing and manufacturing clinically proven, high-quality and cost-effective products that are used in the prevention and treatment of pressure ulcers. Frontier supplies both acute and homecare markets in the UK and internationally.
Kester Capital acquired Frontier Medical Group in 2013 and helped it to grow from a successful focused family-owned business into a leading manufacturer and supplier of healthcare products globally.
The sale of the Frontier Medical Group comes three months after Travers Smith advised the group on its successful refinancing, having previously advised Kester Capital on the sale of Frontier’s Infection Prevention business in a carve-out to Vernacare (backed by H.I.G Capital) in July 2020 and on its original acquisition of the Frontier Medical Group in 2013.
The Travers Smith team was led by Private Equity & Financial Sponsors Partner Will Yates, supported by Senior Associate Tom Hartwright, Associates Alex Watt and Evander Obi and Trainee Katie Bench. Specialist advice was provided by Tax Partner Hannah Manning and Tax Associate Rob Smith, Real Estate Partner Alex Millar and Real Estate Senior Associate Catherine O'Driscoll.
